Navigation Links
Rick Fraunfelder, M.D. of the Casey Vision Correction Center in Portland, Oregon, Joins Elite Group of Surgeons Listed at Trusted LASIK Surgeons
Date:2/26/2009

ced technology to the Pacific Northwest through continuing education of physicians. We are also committed to affordable eye care through collaborative programs and to sharing resources with community providers. Casey Eye Institute is the only free-standing academic eye research center west of Salt Lake City and north of San Francisco. For more information about the Casey Eye Institute, please visit www.ohsucasey.com.

###

Read the full story at http://www.prweb.com/releases/portland-lasik-surgery/dr-rick-fraunfelder/prweb2079284.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Smith & Nephew Launches VISIONAIRE(TM) Patient Matched Technology for Total Knee Replacement
2. The Medical Affairs Company Expands Its Medical Communications Division
3. Environmental Tectonics Corporations BioMedical Divisions Hyperbaric Chambers Address U.S. President Obamas Initiative to Computerize Medical Records
4. Environmental Tectonics Corporations BioMedical Division Announces Sale of Two Monoplace Hyperbaric Chambers
5. Newbridge Securities Corporation Forms BioVentures Division
6. Sirion Therapeutics Partners With Advanced Vision Research (TheraTears(R)) to Promote Products for Retinal and Meibomian Gland Health
7. Free DXA Bone Mineral Density and Body Composition in Clinical Trials Webinars to be Held by M2S DXA Division Expert
8. Free DXA Bone Mineral Density and Body Composition in Clinical Trials Webinars to be Held by M2S DXA Division Expert
9. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
10. Victhom Human Bionics Neurobionix Division receives ISO 13485:2003 Certification for its Design Control System
11. Histogen Featured on Economic Report Television Series
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Rick Fraunfelder, M.D. of the Casey Vision Correction Center in Portland, Oregon, Joins Elite Group of Surgeons Listed at Trusted LASIK Surgeons
(Date:2/26/2015)... (PRWEB) February 26, 2015 On Wednesday, ... to building a nationwide Clostridium difficile (C. diff) awareness ... diff burden study by the Centers for Disease Control ... caused almost half a million infections among Americans in ... nursing homes. , The study also estimates that ...
(Date:2/26/2015)... 26, 2015 Phosphate Therapeutics, ... the first pivotal trial of PT20 in subjects ... disease (DD-CKD), has completed as the pre-specified number ... invented by leading UK-based scientists from the Medical ... is a novel phosphate binder that is based ...
(Date:2/25/2015)... , Feb. 25, 2015 truBrain ... is featured in this week,s Power Pitch segment ... to discuss the company,s traction and growth strategy, ... the crowd funding site CircleUp. The ... that are validated by neurotechnology, while also discussing ...
(Date:2/25/2015)... HONG KONG, Feb. 25, 2015 China Cord ... the "Company"), China,s leading provider of cord blood collection, ... storage services, today announced its preliminary unaudited financial results ... fiscal 2015 ended December 31, 2014. Third ... the third quarter of fiscal 2015 increased by 10.7% ...
Breaking Biology Technology:Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 2Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 3Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 4Phosphate Therapeutics Announces Completion of Subject Recruitment Into the PEACH Pivotal Phase 2 Study of its Novel Phosphate Binder (PT20) for the Treatment of Hyperphosphataemia 2Phosphate Therapeutics Announces Completion of Subject Recruitment Into the PEACH Pivotal Phase 2 Study of its Novel Phosphate Binder (PT20) for the Treatment of Hyperphosphataemia 3CNBC's Power Lunch Features Neurotechnology Start-up truBrain 2China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 2China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 3China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 4China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 5China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 6China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 7China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 8China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 9China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 10China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 11China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 12China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 13China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 14China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 15China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 16China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 17China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 18China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 19China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 20China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 21China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 22
... HARBIN, China, Sept. 15, 2011 /PRNewswire-Asia/ -- China Botanic Pharmaceutical ... "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals ... results for the three months ended July 31, 2011. ... Highlights and Recent Events ...
... New York Stem Cell Summit is releasing effective today an ... the general public understand more accurately the role that autologous ... today. Approximately 1 million patients have been treated ... United States. Harvesting stem cells from adult ...
... 2011 Aperion Biologics, Inc. announced that it has ... the Company,s clinical trial of its Z-Lig™ Anterior Cruciate ... injuries of the knee. The randomized multicenter study commenced ... to provide safety and performance data in the reconstruction ...
Cached Biology Technology:China Botanic Pharmaceutical Reports Third-Quarter Fiscal Year 2011 Results 2China Botanic Pharmaceutical Reports Third-Quarter Fiscal Year 2011 Results 3China Botanic Pharmaceutical Reports Third-Quarter Fiscal Year 2011 Results 4China Botanic Pharmaceutical Reports Third-Quarter Fiscal Year 2011 Results 5China Botanic Pharmaceutical Reports Third-Quarter Fiscal Year 2011 Results 6China Botanic Pharmaceutical Reports Third-Quarter Fiscal Year 2011 Results 7China Botanic Pharmaceutical Reports Third-Quarter Fiscal Year 2011 Results 8New York Stem Cell Summit Issues Adult Stem Cell Fact Sheet 2Aperion Biologics Reaches Midpoint of Enrollment in Z-Lig™ Anterior Cruciate Ligament Reconstruction Medical Device Performance Trial 2
(Date:2/13/2015)... TAIPEI , Feb. 13, 2015 ... service company that aims to transform cancer genomic ... announced that the company has raised US$ 8 million ... Based in Taipei, Taiwan ... tests, ACTDrug™, ACTOnco™. With the aim to implement ...
(Date:2/9/2015)...  Lintec of America recently announced an exclusive license ... macrostructures, including sheets, yarns and ribbons, developed at the ... the vast industrial resources of the global Lintec Group, ... of America is forming the Nano-Science and Technology Center ... on scaling up the manufacturing and commercialization of nano ...
(Date:2/5/2015)... , Jan. 27, 2015   Marvin ... globally deployed, innovative test solutions for military, ... delivery of its TS-323 GENASYS Test ... Company (LMSSC). GENASYS is a high-performance PXI-based ... mission-critical applications that require performance functional testing. ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... University study shows that detergents used to clean up spills ... making it more harmful. "The detergents may be the ... the dispersed oil is diluted and degraded," says Biology professor ... bioavailability and toxicity of the fuel to rainbow trout by ...
... discovered a new approach to prevent bacterial infections from ... Microbiology , Dr Quinn Parks and colleagues describe how ... defence cells to prevent Pseudomonas aeruginosa bacteria ... avoid both the body,s immune mechanisms and antibiotics. ...
... The viscosity, or ,gloopiness, of different parts of cancer ... cancer drugs, according to new images that provide fundamental ... Nature Chemistry today (15 March). ... inside cancer cells whilst they are dying as a ...
Cached Biology News:A sticky business -- how cancer cells become more 'gloopy' as they die 2
...
...
Rabbit polyclonal to YANK2 ( Abpromise for all tested applications). Antigen: A KLH conjugated synthetic peptide selected within aa 300~400 (C terminal region) of human YANK2. Entrez Gene ID:...
Request Info...
Biology Products: